Abstract
On September 15, 2018, the U.S. Food and Drug Administration (FDA) approved subcutaneous fremanezumab, a calcitonin gene-related peptide (CGRP) monocl......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
